In a sudden management revamp, Celgene President and COO Scott Smith will leave his post at the biotech company, effective immediately. Celgene has recently suffered from a series of major setbacks ...

Karen Andersen: Investor sentiment on narrow-moat Celgene appears to be at an all-time low, following the failure of a key Crohn's disease drug and FDA approval delays for multiple sclerosis drug ...

Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of ...

Flatiron Health, a New York City-based oncology technology company, has expanded its relationships with biotechnology company Celgene Corp. and biopharmaceutical company Amgen. Here are three things ...

Celgene’s shares have dropped nearly 30 percent since October, due to slow sales of its psoriasis drug Otezla, an upcoming patent cliff for its multiple myeloma drug Revlimid, and the failure of an ...

US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share. The Seattle-based Juno is a leader in developing ...

The US Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) on Wednesday called on Sanofi-aventis and Celgene to stop broadcasting two of their direct-to-consumer television ...